10 Steps to Better Care® 10 Steps to Stress Control – From Fear to Hope
|
|
|
02.24.12 |
|
TEN STEPS TO STRESS CONTROL - FROM FEAR TO HOPE
- Be open to the idea that stress reduction is achievable and is a worthwhile objective.
- Identify non-cancer-related stresses in your life that may be having a negative impact, such as worry about children or your job.
- Use a scale of 1 - 10 (1 being lowest/10 highest) to assess your stress levels.
Assess your level of stress
- at the time preceding your diagnosis.
- at the time the myeloma became active.
- during a stem cell transplant.
Was the level of stress significant enough to have had a negative health impact?
- Assess the level of stress you experience when you are fearful.
- As you await test results to see if treatment is working.
- When you are worried about relapse.
- When you are starting a new type of therapy.
- Talk to your doctor about your options. Be honest with your doctor, and don’t be afraid to get a second or third opinion if needed.
- Reduce stress where you can. This might call for drastic steps—don’t be afraid to
- Change your job.
- Move if necessary.
- Amend your lifestyle.
- Let others help you. It will help them feel better too.
- Have confidence that the treatment will work!
- Myeloma can be controlled.
- Myeloma can be a “chronic” disease.
- Novel therapies and new approaches to treatment do work.
- Long term survival is feasible.
- Be open to the healing power of hope—it is right there for you:
- From your fellow patients who are doing well,
- From your doctor,
- From your nurse,
- From within yourself.
- From the IMF!
- Turn to the IMF for information and guidance.
- Call the Hotline: 800/452-CURE (2873)
- Go to the website: myeloma.org
- Use the free IMF publications to guide you
|
 related videos
 related articles
|
ASCO 2012: Dr. Pashos - Race- and health-related quality of life among patients newly diagnosed with multiple myeloma
10 PASSI PER CURA MIGLIORE®
10 Steps to Happy Holidays
2011 IMF Holiday Gift Boutique
New Study: The Search for Criteria to Diagnose Active Myeloma at an Early Stage
Comprender El Tratamiento con Dosis Altas con Rescate de Células Madre
Advocacy Update - April 2013
Advocacy Update - March 2013
Advocacy Update - September 2012
Advocacy Update: The Healthcare Landscape in the Aftermath of the 2012 Elections
As the Bill Turns...Episode 3
ASCO 2012: Dr. Pashos - Race- and health-related quality of life among patients newly diagnosed with multiple myeloma
Audio Recording of Consensus on Care: Management of Side Effects of Novel Therapies Teleconference
Breaking News: Pomalyst® (pomalidomide) Approved by the FDA for Relapsed Myeloma
FDA Recognition of Extended Survival with VELCADE® Indicates Important New Progress in Treating the Disease
IMF 6th Annual Comedy Celebration
benefiting the Peter Boyle Research Fund
October 27, 2012
IMF Board Member Edith Mitchell, M.D., FACP, Named 2012 Recipient Of ASCO Humanitarian Award
IMF Nurse Leadership Board (NLB) White Paper on Subcutaneous Velcade® (bortezomib)
IMF Responds to Proposed Changes in CMS PET Scan Policy
It is Officially Myeloma Awareness Month Across the Country!
Live from ASH 2012: Journalists’ Workshop with Leading Myeloma Experts
Live! The Boca Raton Patient & Family Seminar
Living Well with Myeloma Teleconference Series:
How to Prevent Infection in Myeloma Patients
Myelom Merkur - Frühjahr 2012 - #901
MYELOMA AWARENESS MONTH 2012 FACT-A-DAY
Myeloma Canada Announces Recipient of this Year’s Research Grant
Myeloma Minute
April 11, 2013
Myeloma Minute
April 18, 2013
Myeloma Minute
April 26, 2012
Myeloma Minute
February 7, 2013
Myeloma Minute
January 31, 2013
Myeloma Minute
July 26, 2012
Myeloma Minute
June 28, 2012
Myeloma Minute
March 7, 2013
Myeloma Minute
May 17, 2012
Myeloma Minute
November 8, 2012
Myeloma Minute
October 25, 2012
Myeloma Minute
May 24, 2012
Myeloma Today Spring 2013
New! Free Teleconference: Myeloma Updates 2012
Post ASCO/EHA/IMWG Summit
Pomalidomide + carfilzomib trial recruiting patients.
Should Myeloma Patients Get a Flu Shot? If So, Which One?
Special Myeloma Minute on FDA Approved Data for VELCADE®, including long-term survival data
STEP 7: CONSOLIDATION AND MAINTENANCE - ARE THEY NEEDED? REFERENCES
STEP 8: KEEPING TRACK OF THE MYELOMA - MONITORING WITHOUT MYSTERY
Stillwater, Minn., Myeloma Support Group Marks "Centennial" Anniversary
Teleconference: Myeloma Updates 2012
Post ASCO/EHA/IMWG Summit
The Emerging Role of Kyprolis in the Treatment Paradigm
The IMF Spearheads New Coalition’s First Meeting on State Health Exchanges
The Importance of Clinical Trial Participation - A teleconference with Dr. Brian G. M. Durie
September 8,2011
UPCOMING WEBCAST OF THE IMWG CONFERENCE SERIES "MAKING SENSE OF TREATMENT"
Wednesday, June 12, 2013 in Stockhom, Sweden
Клиническое значение электрофореза белковых фракций